Christopher Ward, MD
General Practice · Warrenton, VANPI 1235151739
Payments from drug & device makers
Across 215 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$722
- AbbVie$408
- Pfizer$290
- Amgen$254
- Abbott$218
- Lilly USA, LLC$205
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,60699%
- Education$130%
- Gifts$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 47 | $722 |
| AbbVie(2 entities) | 27 | $408 |
| Pfizer | 17 | $290 |
| Amgen | 18 | $254 |
| Abbott | 4 | $218 |
| Lilly USA, LLC | 16 | $205 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $183 |
| Merck | 11 | $169 |
| Esperion Therapeutics, Inc. | 4 | $124 |
| GSK | 8 | $121 |
| Dexcom, Inc. | 1 | $119 |
| Johnson & Johnson | 7 | $106 |
| AstraZeneca | 4 | $91 |
| Boehringer Ingelheim | 3 | $59 |
| Ironshore Pharmaceuticals Inc. | 1 | $58 |
| Antares Pharma, Inc. | 2 | $41 |
| Arbor Pharmaceuticals, Inc. | 3 | $40 |
| Astellas Pharma US Inc | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Travere Therapeutics, Inc. | 3 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Amarin Pharma, Inc. | 2 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Neos Therapeutics, LP | 2 | $26 |
| Corium, LLC | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Seqirus USA Inc | 1 | $18 |
| Tris Pharma Inc | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Straumann USA LLC | 1 | $16 |
| Cranial Technologies, Inc | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Kaleo, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$136
- DEXCOM G7 GSS (161)$119
How this compares
$3,634 in reported general payments places this provider in the 95th percentile of 2,591 general practice providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 59 | $67,622 |
| OzempicSemaglutide | 33 | $51,756 |
| JardianceEmpagliflozin | 30 | $47,268 |
| TrulicityDulaglutide | 32 | $36,199 |
| XareltoRivaroxaban | 24 | $34,052 |
| TradjentaLinagliptin | 22 | $32,240 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $15,743 |
| JanuviaSitagliptin Phosphate | 17 | $13,944 |
| MyrbetriqMirabegron | 11 | $12,305 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $11,989 |
| Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid | 18 | $4,068 |
| Levothyroxine Sodium | 249 | $2,862 |
| Atorvastatin Calcium | 298 | $2,732 |
| Rosuvastatin Calcium | 207 | $2,188 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 86 | $1,998 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $59 | $79,50852 claims |
| PfizerEliquis | $290 | $67,62259 claims |
| Novo NordiskOzempic | $722 | $51,75633 claims |
| Lilly USA, LLCTrulicity | $205 | $36,19932 claims |
| Johnson & JohnsonXarelto | $106 | $34,05224 claims |
| MerckJanuvia | $169 | $13,94417 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $12,30511 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $2,862249 claims |
| AbbVieSynthroid | $408 | $1,16828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,591 general practice providers in Virginia.
Other general practice in Warrenton
- Mark TurnerRoanoke$986K
- Maryam SabaSpringfield$811K
- Perry JonesRichmond$489K
- Nancy ReevesNorfolk$411K
- Adam HamidiSalem$177K
- Shane CostaReston$174K
- Donald MurryPowhatan$157K
- Marcus YarbroughVirginia Beach$154K
- Adam FoleckNorfolk$149K
- David JonesVirginia Beach$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.